lifestyle.ukuncut.org.uk

Author: Opus Genetics, Inc.

Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference

May 13, 2026
Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update

May 12, 2026
Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases

May 7, 2026
Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study

May 7, 2026
Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program

May 4, 2026
Opus Genetics to Participate in Leading Medical Conferences in May 2026

April 27, 2026
Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital

April 6, 2026
Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026

March 24, 2026
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

March 10, 2026
Opus Genetics to Present at Upcoming Investor Conferences in March 2026

March 3, 2026